A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor

A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor Publisher Pubmed

Faranoush M¹ ; Abolghasemi H² ; Mahboudi F³ ; Toogeh G⁴ ; Karimi M⁵ ; Eshghi P² ; Managhchi M⁴ ; Hoorfar H⁶ ; Dehdezi BK⁷ ; Mehrvar A⁸ ; Khoeiny B⁹ ; Vaziri B³ ; Kamyar K⁹ ; Heshmat R⁴ Show All Authors

Faranoush M¹
Abolghasemi H²
Mahboudi F³
Toogeh G⁴
Karimi M⁵
Eshghi P²
Managhchi M⁴
Hoorfar H⁶
Dehdezi BK⁷
Mehrvar A⁸
Khoeiny B⁹
Vaziri B³
Kamyar K⁹
Heshmat R⁴
Baghaeipour MR¹⁰
Mirbehbahani NB¹¹
Fayazfar R¹²
Ahmadinejad M¹³
Naderi M¹⁴

Show Affiliations

1. Iran University of Medical Sciences, Rasool Akram Hospital, Tehran, Iran
2. Pediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Mofid Children's Hospital, Tehran, Iran
3. Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
4. Thrombosis and Hemostasis Research Center, Tehran University of Medical Sciences, Imam Khomeini Hospital, Tehran, Iran
5. Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
6. Isfahan University of Medical Sciences, Isfahan, Iran
7. Ahwaz University of Medical Sciences, Ahwaz, Iran
8. MAHAK Children's Hospital, Tehran, Iran
9. Aryogen Zist Darou Company, Karaj, Iran
10. Iranian Comprehensive Hemophilia Care Center, Tehran, Iran
11. Golestan University of Medical Sciences, Gorgan, Iran
12. MD, Kerman University of Medical Sciences, Kerman, Iran
13. High Institute of Research, Iranian Blood Transfusion Organization, Tehran, Iran
14. Zahedan University of Medical Sciences, Ahwaz, Iran

Source: Clinical and Applied Thrombosis/Hemostasis Published:2016

Abstract

Introduction: This study compared the efficacy of Aryoseven with Novoseven to control bleeding episodes in patients with hemophilia A with inhibitors. Methods: Sixty-six patients were randomized into 2 groups, with 4 consecutive block randomization. These groups received Aryoseven and Novoseven dosages of 90 to 120 μg/kg intravenously every 2 hours. Results: Median (interquartile range) level of factor VIII (FVIII) inhibitor in groups A and B was 15.0 and 19.0 Bethesda Unit (BU) preadministration. Bleeding onset in group A was 1246 ± 1104 minutes and in group B was 2301 ± 1693 minutes (P =.311). The Kavakli global response scores and treatment success rate was comparable in both the groups. The side effects in groups A (9.7%) and B (2.9%) were comparable. Conclusion: Biosimilar recombinant activated FVII is found to be as effective as Novoseven in the treatment of acute joint bleeding in patients with hemophilia with inhibitors. Its usage will decrease the gaps in hemophilia. © SAGE Publications.

2. The First Discrete Choice Experiment on Usage of Bypassing Agents in Hemophilic Patients in Iran, Iranian Journal of Blood and Cancer (2016)

3. A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency, Clinical and Applied Thrombosis/Hemostasis (2015)

4. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)

5. Comparative Evaluation of the Safety and Efficacy of Recombinant Fviii in Severe Hemophilia a Patients, Journal of Pharmacopuncture (2018)

6. Comparing Efficacy of Receiving Different Doses of Eptifibatide in Bleeding After Percutaneous Coronary Intervention in Patients With Myocardial Infarction, ARYA Atherosclerosis (2019)

7. Impact of Factor Viii and Von Willebrand Factor Plasma Levels on Cerebral Venous and Sinus Thrombosis: Are They Independent Risk Factors?, European Neurology (2011)

Experts (# of related papers)

View all Related Experts

Farshad Roghani (1)

Majid Ghanavat (1)

Style	Citing Format
MLA	Faranoush M, et al.. "A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor." Clinical and Applied Thrombosis/Hemostasis, vol. 22, no. 2, 2016, pp. 184-190.
APA	Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, Managhchi M, Hoorfar H, Dehdezi BK, Mehrvar A, Khoeiny B, Vaziri B, Kamyar K, Heshmat R, Baghaeipour MR, Mirbehbahani NB, Fayazfar R, Ahmadinejad M, Naderi M (2016). A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor. Clinical and Applied Thrombosis/Hemostasis, 22(2), 184-190.
Chicago	Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, Managhchi M, et al.. "A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor." Clinical and Applied Thrombosis/Hemostasis 22, no. 2 (2016): 184-190.
Harvard	Faranoush M et al. (2016) 'A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor', Clinical and Applied Thrombosis/Hemostasis, 22(2), pp. 184-190.
Vancouver	Faranoush M, Abolghasemi H, Mahboudi F, Toogeh G, Karimi M, Eshghi P, et al.. A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor. Clinical and Applied Thrombosis/Hemostasis. 2016;22(2):184-190.
BibTex	@article{ author = {Faranoush M and Abolghasemi H and Mahboudi F and Toogeh G and Karimi M and Eshghi P and Managhchi M and Hoorfar H and Dehdezi BK and Mehrvar A and Khoeiny B and Vaziri B and Kamyar K and Heshmat R and Baghaeipour MR and Mirbehbahani NB and Fayazfar R and Ahmadinejad M and Naderi M}, title = {A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor}, journal = {Clinical and Applied Thrombosis/Hemostasis}, volume = {22}, number = {2}, pages = {184-190}, year = {2016} }
RIS	TY - JOUR AU - Faranoush M AU - Abolghasemi H AU - Mahboudi F AU - Toogeh G AU - Karimi M AU - Eshghi P AU - Managhchi M AU - Hoorfar H AU - Dehdezi BK AU - Mehrvar A AU - Khoeiny B AU - Vaziri B AU - Kamyar K AU - Heshmat R AU - Baghaeipour MR AU - Mirbehbahani NB AU - Fayazfar R AU - Ahmadinejad M AU - Naderi M TI - A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor JO - Clinical and Applied Thrombosis/Hemostasis VL - 22 IS - 2 SP - 184 EP - 190 PY - 2016 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract